{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Mexico Medical Devices news", "home_page_url": "https://sharemaestro.com/newsreel/mx/healthcare/medical-devices/", "feed_url": "https://sharemaestro.com/newsreel/mx/healthcare/medical-devices/feed.json", "description": "Latest Medical Devices company headlines from Mexico, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:eb8d32537916312e97bafca18641db9eb940b0aea9bec1f79127025e04949542", "url": "https://finance.yahoo.com/healthcare/articles/ge-healthcare-ai-ultrasound-launches-191308464.html", "external_url": "https://finance.yahoo.com/healthcare/articles/ge-healthcare-ai-ultrasound-launches-191308464.html", "title": "How GE HealthCare\u2019s New AI Ultrasound Launches Could Shape GEHC\u2019s Diagnostic Edge for Investors", "content_text": "Earlier this month, GE HealthCare introduced the LOGIQ e Xi and LOGIQ e Si laptop ultrasound systems and launched the Invenia ABUS Prime and ABUS StreamVue breast imaging solutions, expanding its AI-enabled and cloud-connected ultrasound portfolio across multiple care settings. These product launches aim to standardize imaging workflows, support remote reading, and address dense-breast screening needs, potentially strengthening GE HealthCare's position in high-value, technologically advanced diagnostics. We'll now examine how this expansion in AI-powered, workflow-focused ultrasound solutions ", "date_published": "2026-08-13T19:13:08+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GEHC"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GEHC", "name": "GE HealthCare Technologies Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b7898e81-253f-4173-8645-02e09a305a8f/"}]}}, {"id": "source:84980dbc017c4e1caacf816c96701866d11ab80a0313de34674c2e716016b3b7", "url": "https://finance.yahoo.com/markets/stocks/articles/strykers-q2-recovery-guidance-support-174900018.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/strykers-q2-recovery-guidance-support-174900018.html", "title": "Can Stryker's Q2 Recovery and Guidance Support a Stronger Second Half?", "content_text": "Stryker Corporation SYK entered the second half of 2026 with momentum restored after the March cybersecurity disruption. Second-quarter sales, earnings and margins improved as production recovered, while management narrowed its full-year outlook. The next test is execution. Stryker must keep normalizing production, convert elevated backlog into shipments and support a broad product launch cycle. Those factors will determine whether the stronger second half embedded in management's expectations materializes. Stryker's Q2 Recovery Rebuilt Momentum Stryker reported second-quarter net sales of $6.", "date_published": "2026-08-13T17:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "SYK"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/8cb91a3d-97c1-4ed6-a1cb-ce513180216f/"}]}}, {"id": "source:5971b49dee342142efd77297a630f9275b5f8928066a404b0980f77284728a39", "url": "https://finance.yahoo.com/markets/stocks/articles/stryker-13-6-3-months-174900364.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/stryker-13-6-3-months-174900364.html", "title": "Stryker Up 13.6% in 3 Months as Recovery Gains Strength, What's Next?", "content_text": "Stryker Corporation SYK shares have risen 13.6% in the past three months, outpacing the Zacks Medical sector's 12.9% gain and the S&P 500's 1.7% advance. The move has coincided with a sharper operating recovery after a difficult first quarter. The investor question is whether improving sales, margins and production can keep supporting the stock, or whether execution demands and a richer relative valuation now make the next leg higher harder to achieve.Zacks Investment Research Image Source: Zacks Investment Research Why Stryker's Three-Month Rally Has Support Stryker's second-quarter results g", "date_published": "2026-08-13T17:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "SYK"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/8cb91a3d-97c1-4ed6-a1cb-ce513180216f/"}]}}, {"id": "source:0b0fb9490ab43a14a6f259c15ca65616328960edddf47dcbe17e6d04df9ccb3e", "url": "https://finance.yahoo.com/healthcare/articles/heres-why-pediatrix-medical-smart-155300567.html", "external_url": "https://finance.yahoo.com/healthcare/articles/heres-why-pediatrix-medical-smart-155300567.html", "title": "Here's Why Pediatrix Medical Can Be a Smart Addition to Your Portfolio", "content_text": "Pediatrix Medical Group, Inc. MD is a physician services provider company that offers a range of services across various specialties, including obstetrics, maternal-fetal medicine and neonatology, complemented by multiple pediatric subspecialties. The company has gained 23.9% in the year-to-date period, outperforming the industry's 1.2% growth. MD \u2014 with a market cap of $2.2 billion \u2014is well-poised for growth, benefiting from stronger cash collections, a favorable payer mix and higher patient acuity in neonatology. Strategic acquisitions are adding further support to revenue and earnings growt", "date_published": "2026-08-13T15:53:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GMED"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GMED", "name": "Globus Medical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/972d701d-351a-4b7f-9a57-4b2bb8d46398/"}]}}, {"id": "source:3bec54d3bf7ec8c391f4104861349aadc0e30456575983739eca1728f8680038", "url": "https://finance.yahoo.com/markets/stocks/articles/gehc-lmat-better-value-stock-154003397.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/gehc-lmat-better-value-stock-154003397.html", "title": "GEHC or LMAT: Which Is the Better Value Stock Right Now?", "content_text": "Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and LeMaitre Vascular (LMAT). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specif", "date_published": "2026-08-13T15:40:03+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GEHC"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GEHC", "name": "GE HealthCare Technologies Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b7898e81-253f-4173-8645-02e09a305a8f/"}]}}, {"id": "source:a57ab9ff6bf4a20b8173e3a2b86a423a6a332c7531d73d20ba9a5faee830400f", "url": "https://finance.yahoo.com/healthcare/articles/revvity-launches-superflex-prenatal-screening-140000308.html", "external_url": "https://finance.yahoo.com/healthcare/articles/revvity-launches-superflex-prenatal-screening-140000308.html", "title": "Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs", "content_text": "Revvity, Inc. RVTY recently announced the launch of the SuperFlex prenatal screening system, a compact, CE-IVDR-certified automated immunoassay instrument designed to expand access to prenatal and preeclampsia testing. Purpose-built for small to mid-sized laboratories and clinics, the platform is intended to bring reliable, rapid in-house screening capabilities to lower-volume testing environments. SuperFlex initially will be available in markets accepting CE-marked instruments, with expansion into Asia-Pacific planned for late 2026. Per management, the SuperFlex system represents a significan", "date_published": "2026-08-13T14:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GMED"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GMED", "name": "Globus Medical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/972d701d-351a-4b7f-9a57-4b2bb8d46398/"}]}}, {"id": "source:627655aaef2ff927e3ded200aca76be0526bafd2af9b4cfcf1b6643417140ea2", "url": "https://finance.yahoo.com/healthcare/articles/insulet-corporation-podd-wearable-pod-130437669.html", "external_url": "https://finance.yahoo.com/healthcare/articles/insulet-corporation-podd-wearable-pod-130437669.html", "title": "Insulet Corporation\u2019s (PODD) Wearable Pod Tech Finds New Frontier", "content_text": "Alpha Wealth Funds, LLC, an investment management company, released its Q2 2026 letter for the \"Insiders Fund\". A copy of the letter is available to download here. The Fund lost 1.45% in June, while it was up 8.43% for the 2nd quarter and 0.75% YTD. This compares to the S&P 500's -0.95%, 15.2%, and 9.98% returns, respectively, over the same period. The fund underperformed while the S&P 500 and Nasdaq-100 posted their best quarter in six years. A significant factor in this decline is a ~30% concentration in Alphabet stock, which shifted from a cash-generating asset to a capital-intensive postur", "date_published": "2026-08-13T13:04:37+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "PODD"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PODD", "name": "Insulet Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/ddc4e846-4b3d-49f0-9696-0f35675b981e/"}]}}, {"id": "source:44eba28bf78d020546e41c688eb9802fde66248b39f513d8609af0d73f4e7a33", "url": "https://finance.yahoo.com/healthcare/articles/whats-backing-abbotts-established-pharmaceuticals-124900457.html", "external_url": "https://finance.yahoo.com/healthcare/articles/whats-backing-abbotts-established-pharmaceuticals-124900457.html", "title": "What's Backing Abbott's Established Pharmaceuticals Division Growth", "content_text": "Abbott Laboratories' ABT Established Pharmaceuticals Division (\"EPD\") continues to be a solid growth contributor, supported by its broad portfolio of branded generic medicines and strong commercial presence across emerging markets. In the second quarter of 2026, EPD sales increased 8.4% on a reported basis and 8.7% on a comparable basis. Key Emerging Markets delivered 10.7% comparable sales growth, driven by double-digit growth in several countries across Latin America and Asia Pacific. The strong performance highlights the benefits of EPD's diversified geographic footprint and its ability to ", "date_published": "2026-08-13T12:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABT"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/087c1c3d-b101-4e93-9e9f-1d2d4bc0dadf/"}]}}, {"id": "source:e62631285d7721245ec3e28a17d057d0d95d03a031f7951167d433420fe5c569", "url": "https://finance.yahoo.com/healthcare/articles/wolfe-research-downgrades-stryker-upgrades-123705436.html", "external_url": "https://finance.yahoo.com/healthcare/articles/wolfe-research-downgrades-stryker-upgrades-123705436.html", "title": "Wolfe Research downgrades Stryker, upgrades Abbott in med-tech shuffle", "content_text": "Investing.com -- Wolfe Research made two rating changes across large-cap medical devices, downgrading Stryker while upgrading Abbott Laboratories on Thursday. Analyst Mike Polark cut Stryker to Peer Perform, citing a demanding second-half setup following the company's March cyber disruption. He said the June quarter \"wasn't a huge catch up thus year not yet de-risked,\" leaving \"a higher-than-normal burden on 2H to deliver.\" As a result, Wolfe sees the near-term skew to estimates \"leans negative,\" with growth \"more likely to slow to 8% vs speed up to 10% in 2027.\" The firm flagged that Stryker'", "date_published": "2026-08-13T12:37:05+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "SYK"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/8cb91a3d-97c1-4ed6-a1cb-ce513180216f/"}]}}, {"id": "source:1e0cde33e45bc82a30375dfc4c94e9b07cb308ddf22aac26c5b00ca8d2be89dd", "url": "https://finance.yahoo.com/m/157854b1-0d26-3fa0-a565-352a2ee3928c/revisiting-former-stock-picks.html", "external_url": "https://finance.yahoo.com/m/157854b1-0d26-3fa0-a565-352a2ee3928c/revisiting-former-stock-picks.html", "title": "Revisiting Former Stock Picks Medtronic, Quantas Services, Lennar", "content_text": "Reassessing stock picks is one of the best habits an investor can build. Watch Doug discuss recent stock picks, provide input on the current market environment\u2014and take your questions. The daily chart illustrates how well the stock has performed relative to its peers on the ratio chart against the over the past two months. Continue Reading", "date_published": "2026-08-13T04:43:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "MDTN"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDTN", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/29c47170-35d2-4239-972f-dcfecaf5bd5e/"}]}}, {"id": "source:d1ff4abfa86d55712f20d8ea819cc03bccd201b893a8f3c5f1d312a0f3e243cf", "url": "https://finance.yahoo.com/markets/stocks/articles/globus-medical-gmed-stock-sees-031738212.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/globus-medical-gmed-stock-sees-031738212.html", "title": "Globus Medical (GMED) Stock Sees Modest Fair Value Cut As Analysts Trim Growth Views", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Globus Medical has seen its assessed fair value cut from US$107.42 to US$103.23, a modest 3.9% trim that reflects a cooler view on upside from current levels. Recent research has highlighted a split narrative, with some analysts pointing to earnings strength and integration progress, while others focus on softer growth expectations and a tighter trading range for price targets. As you read on, you will see how these differing views fit together and how to ", "date_published": "2026-08-13T03:17:38+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GMED"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GMED", "name": "Globus Medical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/972d701d-351a-4b7f-9a57-4b2bb8d46398/"}]}}, {"id": "source:d7fa608c9de0a99190afe7e397e87f0eca08bd95a58d0871006c21d0621a0412", "url": "https://finance.yahoo.com/markets/stocks/articles/globus-medical-gmed-bargain-zacks-020925308.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/globus-medical-gmed-bargain-zacks-020925308.html", "title": "Is Globus Medical (GMED) A Bargain On Its Zacks Upgrade And Reaffirmed Guidance?", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Globus Medical (GMED) has been in focus after a recent upgrade to Zacks Rank #1, which came shortly after the company reaffirmed its 2026 revenue guidance and released its latest quarterly earnings. See our latest analysis for Globus Medical. Over the past year, Globus Medical has seen a 36.44% total shareholder return and a 10.96% 90 day share price return. This suggests momentum has been building again around the recent earnings update and reaffirmed 202", "date_published": "2026-08-13T02:09:25+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GMED"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GMED", "name": "Globus Medical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/972d701d-351a-4b7f-9a57-4b2bb8d46398/"}]}}, {"id": "source:19c448bd17978ba69542b6669c5c4089a3b8247df77ddaecd09b8b118d2b7c96", "url": "https://finance.yahoo.com/healthcare/articles/abbott-laboratories-abt-ties-lingo-211304863.html", "external_url": "https://finance.yahoo.com/healthcare/articles/abbott-laboratories-abt-ties-lingo-211304863.html", "title": "Abbott Laboratories (ABT) Ties Lingo Glucose Data To AI Health Tools", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Abbott Laboratories (NYSE:ABT) and Google Health announced a multi year partnership to integrate Abbott's Lingo biowearable glucose data with Google's AI driven consumer health tools. The collaboration aims to feed continuous glucose monitoring insights into the Google Health app to support personalized metabolic health tracking and coaching. The companies plan to run one of the largest real world metabolic health studies using anonymized Lingo data combined with Google's AI capabilities. The agreement is positioned to support Abbott's role in personalized wellness and wearables by linking its sensor technology with widely used digital health platforms. For investors watching how AI is reshaping consumer health, this Abbott Laboratories move is one piece of a wider opportunity set that includes companies supplying the infrastructure behind these tools, which you can explore through 57 AI infrastructure stocks.NYSE:ABT Earnings & Revenue Growth as at Aug 2026 Abbott Laboratories is a global medical equipment company that discovers, develops, manufactures, and sells health care products. This collaboration integrates its biowearable sensor technology into a consumer-facing AI health ecosystem rather than keeping it purely in clinical settings. We've flagged 2 risks for Abbott Laboratories. See which could impact your investment. How the Google Health tie up feeds into Abbott Laboratories' AI and device thesis For Abbott Laboratories, this partnership lines up closely with the Narrative catalyst around ongoing innovation in high margin medical technologies such as glucose sensors and software integrations. Plugging Lingo data into Google Health Coach strengthens the case that Abbott can extend its glucose monitoring expertise into broader consumer metabolic health, not just diabetes care. At the same time, it touches a key risk in the Narrative around competitive pressure and potential commoditization in continuous glucose monitoring, since more open data ecosystems can make it easier for rivals and payers to compare offerings on price and features. If we take a look at the community Narrative for Abbott Laboratories, we can see how this news fits into the bigger investment story. The clearest early signal that this is gaining traction will be how quickly Lingo integrations appear in the Google Health app later this year and whether Abbott discloses user adoption or engagement metrics for Lingo within that ecosystem. Any future commentary on how these AI driven insights influence product development in glucose monitoring or other medical devices would also help show whether this deal is translating into the kind of cross segment synergies the Narrative highlights. Story Continues For the full picture including more risks and rewards, check out the complete Abbott Laboratories analysis. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ABT. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com View Comments", "date_published": "2026-08-12T21:13:04+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ABT"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/087c1c3d-b101-4e93-9e9f-1d2d4bc0dadf/"}]}}, {"id": "source:7835a6b4b376fa6f740670085bc029bc18c05ead14857e55d06d331eda00396f", "url": "https://finance.yahoo.com/markets/stocks/articles/dxcm-stock-worth-buying-growth-183600592.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/dxcm-stock-worth-buying-growth-183600592.html", "title": "Is DXCM Stock Worth Buying as Growth Improves but Valuation Stretches?", "content_text": "DexCom, Inc. DXCM is entering the second half of 2026 with healthier margins, broader reimbursement and a larger continuous glucose monitoring opportunity. The investment question is whether that improving setup is enough to justify a premium valuation. Growth catalysts remain visible across U.S. coverage, product upgrades and international expansion. Yet competition, litigation and a forward earnings multiple above key benchmarks leave less room for execution misses. DXCM's Growth Case Is Still Broadening DexCom's addressable market is widening beyond intensive insulin users. All four of the largest U.S. commercial pharmacy benefit managers now cover people with type 2 diabetes who are not using insulin, representing more than 7 million covered lives. Penetration still has room to improve even before additional reimbursement wins. Roughly 9 million people in the United States already have continuous glucose monitoring coverage but are not using the technology, giving DXCM a sizable pool of potential new users. DexCom's Valuation Leaves Less Room for Error That runway is not cheap. DXCM trades at a forward 12-month price-to-earnings ratio of 30.68, above 27.25 for the Zacks sub-industry, 21.15 for the Medical sector and 20.66 for the S&P 500. The premium raises the hurdle for future results. Revenue growth, estimate revisions and margin expansion can support a higher multiple, but investors are already paying for a meaningful portion of that progress. Any slowdown in patient additions, reimbursement or operating leverage could pressure the valuation.Zacks Investment Research Image Source: Zacks Investment Research DXCM's Coverage and Product Catalysts Matter Product execution strengthens the growth argument. DexCom is rolling out G7 15 Day and expects to convert nearly half of its U.S. customer base to the system by year-end 2026. Health Canada has cleared G7 15 Day, while Dexcom Flex has launched in Germany for selected type 2 populations. Clinical evidence could broaden the runway further. In the CONNECT trial, DexCom CGM users with type 2 diabetes not using insulin posted a 1.6% A1c improvement, spent more than five additional hours per day in range and recorded 97% median CGM use. DexCom has submitted the data to CMS in support of expanded non-insulin coverage. DexCom's Competition and Litigation Temper Upside The category remains crowded. Abbott Laboratories ABT competes through its FreeStyle Libre continuous glucose monitoring franchise. MiniMedGroup MMED, the recently divested business of Medtronic, also offers continuous glucose monitoring and integrated diabetes technologies, while Senseonics Holdings, Inc. SENS markets the implantable Eversense 365 system. Story Continues More viable alternatives can give payers leverage in negotiations over pricing, rebates and formulary placement. DexCom also faces ongoing patent disputes plus securities, derivative and product-related class actions. These issues may add legal expense and execution uncertainty even if underlying demand remains healthy. DXCM's Signal Mix Supports Patience The balance of evidence favors patience over an aggressive entry. Earnings estimates for 2026 and 2027 have moved up 2.7% and 1.2% over the past 60 days to $2.65 and $3.08, respectively. Second-quarter adjusted gross margin reached 64.1% and adjusted operating margin improved to 25.1%.Zacks Investment Research Image Source: Zacks Investment Research DXCM currently carries a Zacks Rank #3 (Hold). Likewise, Abbott and Senseonics carry a Zacks Rank of 3, while MiniMed has a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. With estimates rising and margins improving, the fundamental direction is constructive. The premium valuation, competitive pressure and litigation risk still argue for waiting for either a better price or further proof that growth can sustain the current multiple. Want the latest recommendations from Zacks Investment Research? Tod", "date_published": "2026-08-12T18:36:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ABT"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/087c1c3d-b101-4e93-9e9f-1d2d4bc0dadf/"}]}}, {"id": "source:cb1fb61e2d7b4c9de7e8f3ba544e3579767d3406ea22a6d11486614a7eb1e9aa", "url": "https://finance.yahoo.com/healthcare/articles/dxcm-stock-nearly-35-ytd-183400790.html", "external_url": "https://finance.yahoo.com/healthcare/articles/dxcm-stock-nearly-35-ytd-183400790.html", "title": "DXCM Stock Up Nearly 35% YTD: Will the Uptrend Continue in the Rest of 2026?", "content_text": "DexCom DXCM stock has rebounded sharply in 2026, gaining 34.8% after falling 14.7% in 2025, as investors increasingly recognize the company's improving growth profile and expanding continuous glucose monitoring (CGM) opportunity. The company's share price performance so far this year has outperformed the industry's 6.9% decline and S&P 500 Index's 13.1% gain. The second-quarter performance reflected recovery, with revenues rising 13% year over year and organic growth reaching 12%. U.S. revenues increased 11%, while international revenues jumped 19%, reflecting broader reimbursement, market-share gains and stronger patient starts. DexCom is expanding beyond its traditional insulin-dependent customer base. New evidence supporting CGM use in non-insulin Type 2 diabetes, broader international access and new products such as G7 15 Day and Smart Basal could materially expand the addressable market through 2026 and beyond. YTD Performance of DXCM vs IndustryZacks Investment Research Image Source: Zacks Investment Research What Is Fueling DXCM's Growth? Non-Insulin Type 2 Diabetes Could Expand the Addressable Market: DexCom's CONNECT trial could become an important growth catalyst by strengthening the case for CGM among non-insulin Type 2 patients. The study produced a 1.6% A1c improvement over six months, while commercial coverage has expanded across the four largest U.S. PBMs, reaching more than 7 million eligible patients. Broader reimbursement could significantly accelerate adoption beyond DexCom's traditional customer base. G7 15 Day Is Strengthening Product Adoption: The G7 15 Day rollout is creating a meaningful product-cycle opportunity. DexCom expects nearly 50% of its U.S. customer base to transition to the system by year-end, supported by an improved algorithm, longer wear time and stronger customer satisfaction. G7 15 Day also received Health Canada clearance, opening another avenue for international expansion. The product transition contributed to a roughly 400-basis-point improvement in second-quarter gross margin. International Expansion Provides Another Growth Lever: International markets are growing increasingly important to DexCom's growth trajectory. International revenues increased 19% in the second quarter, with organic growth of 16%. France and Canada benefited from expanding reimbursement access. DexCom is also rolling out Flex, its 15-day sensor for select Type 2 basal and non-insulin markets. Continued reimbursement wins could help the company replicate the share gains achieved in recently opened markets. Story Continues DexCom Is Building a Broader Digital Diabetes Platform: DexCom is expanding beyond sensor hardware through software and digital-health capabilities. The redesigned Stelo app adds AI-driven insights and enhanced food logging, while Smart Basal has reduced the time needed to reach an optimal basal insulin dose to about three weeks in pilot practices. The company also acquired Nutrisense, a CGM-data nutrition platform, creating additional potential for personalized metabolic-health services. A Glance at DXCM's Estimates The Zacks Consensus Estimate for DXCM's 2026 and 2027 earnings per share (EPS) implies year-over-year growth of 26.8% and 16.6%, respectively, to $2.64 and $3.08. In the past 60 days, the consensus mark for the company's 2026 EPS has improved 2.7%. Revenues for 2026 are projected to grow 12.1% to $5.23 billion and another 11.6% to $5.83 billion in 2027.Zacks Investment Research Image Source: Zacks Investment Research Competition Remains a Major Variable The CGM market remains highly competitive, with Abbott ABT, MiniMed MMED and Senseonics SENS pursuing distinct strategies. Abbott remains DexCom's most formidable direct rival, with Diabetes Care CGM sales exceeding $2 billion in the second quarter, reflecting growth of 9.5%. Abbott also received CE Mark clearance for Libre Duo, its glucose-ketone monitoring sensor. MiniMed is strengthening its ecosystem, with CGM revenues growing ", "date_published": "2026-08-12T18:34:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ABT"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/087c1c3d-b101-4e93-9e9f-1d2d4bc0dadf/"}]}}, {"id": "source:c6eafdfc22d548b9106fb663c201452672aac2c3d6904920bde827aebe3c9ab0", "url": "https://finance.yahoo.com/healthcare/articles/isrgs-us-procedure-growth-slows-183300794.html", "external_url": "https://finance.yahoo.com/healthcare/articles/isrgs-us-procedure-growth-slows-183300794.html", "title": "ISRG's US Procedure Growth Slows: Is ACA Headwind a Temporary Concern?", "content_text": "Intuitive Surgical ISRG has faced a moderation in U.S. procedure growth during the first half of 2026, but management's commentary suggests the slowdown is more likely a temporary demand-timing issue than evidence of a structural deterioration. U.S. da Vinci procedures grew 12% in the second quarter, down from 14% in the first quarter. da Vinci procedure growth was 17% in the fourth quarter of 2025. Management pointed to a modest adverse impact from the expiration of enhanced ACA premium subsidies. Customer feedback indicated that changes in insurance coverage and premium dynamics affected the", "date_published": "2026-08-12T18:33:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GMED"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GMED", "name": "Globus Medical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/972d701d-351a-4b7f-9a57-4b2bb8d46398/"}]}}, {"id": "source:e2e53014098505128ba9b042fa06f1f76e2cbe50dbb782d539fd1cf552748935", "url": "https://finance.yahoo.com/markets/stocks/articles/dxcm-rallies-52-5-3-183300640.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/dxcm-rallies-52-5-3-183300640.html", "title": "DXCM Rallies 52.5% in 3 Months. Can the Stock Keep Climbing From Here?", "content_text": "DexCom, Inc. DXCM shares have climbed 52.5% in the past three months, a sharp re-rating that raises the standard for further gains. The next leg depends less on momentum alone and more on whether earnings growth, margin expansion and new-market access can keep pace with higher expectations. Recent results support the fundamental case, but the stock's premium valuation leaves less room for disappointment. Investors now have to weigh improving execution against competition and litigation risk. DXCM's 52.5% Rally Outpaces Key Benchmarks DXCM's three-month gain easily exceeds the 18.3% rise for th", "date_published": "2026-08-12T18:33:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "DXCM", "ABT"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "DXCM", "name": "DexCom, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/0133fa98-cf6a-4130-9df8-b57b1bec5c41/"}, {"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/087c1c3d-b101-4e93-9e9f-1d2d4bc0dadf/"}]}}, {"id": "source:0f3f921f4e754d1dc87f0170b5d5e6487b23b1075953275044ad300b7bd58823", "url": "https://finance.yahoo.com/healthcare/articles/dexcoms-raised-2026-outlook-sustain-183300821.html", "external_url": "https://finance.yahoo.com/healthcare/articles/dexcoms-raised-2026-outlook-sustain-183300821.html", "title": "Can DexCom's Raised 2026 Outlook Sustain Stronger Margin Momentum?", "content_text": "DexCom, Inc. DXCM raised its 2026 revenue and margin outlook after a stronger second quarter, shifting more attention toward profitability. The question is whether better gross margin and operating leverage can persist as organic growth improves. The guidance increase is encouraging, but foreign exchange, manufacturing investment and product-transition costs still matter. Sustaining the margin step-up will require continued execution across products, geographies and channels. DexCom's Q2 Results Reset the 2026 Baseline DexCom reported second-quarter 2026 revenues of $1.31 billion, up 13.1% year over year, while adjusted earnings reached 70 cents per share. Adjusted operating income increased 48% to $328.3 million, with the adjusted operating margin expanding to 25.1%. DexCom, Inc. Revenue (Quarterly)DexCom, Inc. Revenue (Quarterly) DexCom, Inc. revenue-quarterly | DexCom, Inc. Quote The operating backdrop was broad. U.S. revenues rose 11% to $933.4 million, while international revenues increased 19% to $375 million. International organic growth was 16%, supported by reimbursement expansion and adoption in markets including France and Canada. DXCM's Raised Margin Outlook Shows Better Leverage Management now expects 2026 revenues of $5.18-$5.25 billion, up from the prior $5.16-$5.25 billion range. The updated outlook implies 11-13% annual growth and incorporates stronger organic growth expectations. Profitability guidance moved higher as well. DexCom raised its adjusted gross margin forecast to about 64%, adjusted operating margin guidance to 23.5%-24% and adjusted EBITDA margin guidance to 31.5%-32%. Those revisions make operating leverage a larger part of the 2026 thesis rather than leaving the story dependent mainly on revenue growth. DexCom's G7 15 Day Rollout Supports Profitability The G7 15 Day transition is helping the margin profile through product mix and manufacturing efficiency. Second-quarter adjusted gross margin reached 64.1%, up 400 basis points year over year, as manufacturing efficiencies and the initial customer switchover to G7 15 Day supported results. The rollout also broadens the product opportunity. DexCom expects to convert nearly half of its U.S. customer base to G7 15 Day by year-end 2026. Health Canada has cleared the system, while Dexcom Flex has launched in Germany, giving the company additional paths to extend 15-day sensor economics internationally. DXCM's FX and Execution Risks Could Offset Progress The higher outlook still carries offsets. DexCom expects a roughly $15 million foreign-exchange headwind to second-half 2026 international revenues. The company is also investing in its Ireland manufacturing facility, while the transition away from G6 brings inventory and execution costs that can complicate near-term efficiency gains. Story Continues Competition can further influence pricing, rebates and channel mix. Abbott Laboratories ABT continues to expand its FreeStyle Libre continuous glucose monitoring franchise, including use in type 2 diabetes. Senseonics Holdings, Inc. SENS markets the implantable Eversense 365 system, giving patients and payers another differentiated continuous glucose monitoring option. DexCom's Signal Check Keeps Expectations Grounded The margin upgrades improve DXCM's fundamental setup, and earnings estimates have moved higher. Over the past 60 days, estimates for 2026 and 2027 rose 2.7% and 1.2% to $2.65 and $3.08 per share, respectively. The stock, however, trades at 30.7X forward 12-month earnings, above 27.3X for the Zacks sub-industry, 21.2X for the Medical sector and 20.7X for the S&P 500.Zacks Investment Research Image Source: Zacks Investment Research DXCM currently carries a Zacks Rank #3 (Hold). Likewise, Abbott and Senseonics carry a Zacks Rank of 3. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Raised guidance and improving estimates support the margin story, but the valuation premium, foreign-exchange pressure and execution ", "date_published": "2026-08-12T18:33:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ABT"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/087c1c3d-b101-4e93-9e9f-1d2d4bc0dadf/"}]}}, {"id": "source:3ea6e701ff7683fcac8c3f9bcb8cf44f16546528c61754b8293901a2b441debc", "url": "https://finance.yahoo.com/markets/commodities/articles/latest-global-whey-protein-market-173000212.html", "external_url": "https://finance.yahoo.com/markets/commodities/articles/latest-global-whey-protein-market-173000212.html", "title": "[Latest] Global Whey Protein Market Size/Share Worth USD 26.04 Billion by 2034 at a 7.56% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)", "content_text": "Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Whey Protein Market size & share revenue was valued at approximately USD 12.58 Billion in 2024 and is expected to reach USD 13.52 Billion in 2025 and is expected to reach around USD 26.04 Billion by 2034, at a CAGR of 7.56% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Abbott, Alpavit, Arla Foods, Carbery Group, Davisco Foods International, Inc., Fonterra Co-operative Group Ltd., Glanbia plc, Hilmar Cheese Company, Inc., LACTALIS Ingredients, Leprino Foods Company, Maple Island, Inc., Milk Specialties, Milkaut SA, Nestle S.A., Nutricia (Danone), Olam International, Sanofi S.A., Saputo Inc., Wheyco GmbH and others. Austin, TX, USA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled \"Whey Protein Market Size, Trends and Insights By Type (Whey Protein Isolates (WPI), Whey Protein Concentrates (WPC), Whey Protein Hydrolysates (WPH)), By Application (Sports Nutrition, Dietary Supplements, Infant Formula, Food Additives, Beverages, Feed), By End Users (Athletes, Bodybuilders, Lifestyle Users), By Distribution Channel (Supermarkets/Hypermarkets, Convenience Stores, Specialty Stores, Online Stores), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 \u2013 2034\" in its research database. \"According to the latest research study, the demand of global Whey Protein Market size & share was valued at approximately USD 12.58 Billion in 2024 and is expected to reach USD 13.52 Billion in 2025 and is expected to reach a value of around USD 26.04 Billion by 2034, at a compound annual growth rate (CAGR) of about 7.56% during the forecast period 2025 to 2034.\" Click Here to Access a Free Sample Report of the Global Whey Protein Market @ https://www.custommarketinsights.com/request-for-free-sample/?reportid=72482 Overview According to industry experts at CMI, the implementation of new strategies and technologies by manufacturers presents lucrative opportunities for players in the Whey Protein Market during the forecast period. Furthermore, the growing significance of organized retailing is expected to drive the future growth of the market. Request a Customized Copy of the Whey Protein Market Report @https://www.custommarketinsights.com/request-for-customization/?reportid=72482 Key Trends & Drivers Story Continues Clean-Label and Natural Products: There is a growing demand for clean-label whey protein products as consumers are now demanding more transparency in their supplements and to use more natural ingredients. A big indicator of this trend is the preference for products made without artificial ingredients, colors, or preservatives. Organic whey protein and non-GMO products are most popular in the premium products. The brands are also seeking to attract the consumers who want transparency regarding ethical sourcing and traceability. The clean-label trend supports the trend for healthier eating and sustainability, prompting manufacturers to have clearer labelling practices and reformulate products to meet consumers' desires for authentic and pure supplements. Growth of Ready-to-Drink (RTD) Beverages: Convenience-based living has allowed demand for ready-to-drink whey protein to rise. More consumers prefer portable and on-the-go options that supply an adequate level of protein without preparation. RTD shakes and drinks that provide protein fortification have quickly become commonplace for athletic consumers, busy working individuals, and lifestyle consumers. Flavourings, texture, variety, active ingredients (less sugar), etc. are innovating at exciting rates to make beverages more attractive to consumers from a wider range of market segments. The beverages may also be more/less expensive, but the premium packaging and singl", "date_published": "2026-08-12T17:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ABT"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/087c1c3d-b101-4e93-9e9f-1d2d4bc0dadf/"}]}}, {"id": "source:2100e637b2916ecb584e6b354b330a6f85d10b7b8fa369baf89de13620dc54c4", "url": "https://finance.yahoo.com/markets/stocks/articles/two-years-growth-barely-change-172001135.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/two-years-growth-barely-change-172001135.html", "title": "Two Years Of Growth Barely Change What You Pay For Intuitive Surgical", "content_text": "Photo by 127071 on Pixabay Consensus growth takes only a modest slice off the multiple, and the company has not yet set the instrument pricing that lands inside those two years. Intuitive Surgical (ISRG) trades at about $401.23, roughly 32% below its 52-week high and down about 15% over the past twelve months while the S&P 500 returned 22%. A fall that size usually leaves a stock cheap. This one still costs about 37.7 times its last twelve months of adjusted earnings, and what happens to that number by 2027 turns on a price the company has not set. Where The Multiple Actually Lands In 2027 Ana", "date_published": "2026-08-12T17:20:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GMED"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GMED", "name": "Globus Medical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/972d701d-351a-4b7f-9a57-4b2bb8d46398/"}]}}, {"id": "source:3673fa8d0714b3642df47eb0166fd1bfa08deb202bed3f54d750f36de250eb04", "url": "https://finance.yahoo.com/healthcare/articles/ge-healthcare-gehc-upgraded-buy-160002939.html", "external_url": "https://finance.yahoo.com/healthcare/articles/ge-healthcare-gehc-upgraded-buy-160002939.html", "title": "GE HealthCare (GEHC) Upgraded to Buy: Here's What You Should Know", "content_text": "GE HealthCare Technologies (GEHC) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. Since a changing earnings picture is a powerful factor influencing near-term stock price", "date_published": "2026-08-12T16:00:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "GEHC"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GEHC", "name": "GE HealthCare Technologies Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b7898e81-253f-4173-8645-02e09a305a8f/"}]}}, {"id": "source:994884ad159881682eed991e1e25206c3bf95661824968f529358532db52d15d", "url": "https://finance.yahoo.com/healthcare/articles/heres-why-add-brightspring-stock-154100785.html", "external_url": "https://finance.yahoo.com/healthcare/articles/heres-why-add-brightspring-stock-154100785.html", "title": "Here's Why You Should Add BrightSpring Stock to Your Portfolio Now", "content_text": "BrightSpring Health Services, Inc. BTSG is well-poised for growth in the coming quarters, backed by strong momentum in Provider Services, expanding specialty and infusion operations, successful integration of acquired home health assets and a scalable home-based care platform. However, the Inflation Reduction Act (IRA)-related reimbursement pressure, brand-to-generic conversion headwinds and customer exits in Home and Community Pharmacy could create uneven growth trends and weigh on near-term margin realization through 2026. This Zacks Rank #1 (Strong Buy) company's shares have rallied 54.6% i", "date_published": "2026-08-12T15:41:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GMED"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GMED", "name": "Globus Medical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/972d701d-351a-4b7f-9a57-4b2bb8d46398/"}]}}, {"id": "source:2811532d7a8577576cfceab76f423ba62c11efd9b352e736640b5f1c8791702a", "url": "https://finance.yahoo.com/healthcare/articles/npce-q2-earnings-beat-estimates-152200716.html", "external_url": "https://finance.yahoo.com/healthcare/articles/npce-q2-earnings-beat-estimates-152200716.html", "title": "NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up", "content_text": "NeuroPace, Inc. NPCE reported a second-quarter 2026 loss per share of 18 cents, compared with a loss of 30 cents in the year-ago period. The figure beat the Zacks Consensus Estimate by 5.3%. Shares of NPCE were down approximately 2.3% during after-market trading following the second-quarter results. The company's shares have lost 2.6% in the year-to-date period compared with the industry's decline of 5.9%. However, the broader S&P 500 Index has increased 12.5% in the same time frame.Zacks Investment Research Image Source: Zacks Investment Research NPCE's Q2 Revenues Show Core Momentum NeuroPac", "date_published": "2026-08-12T15:22:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GMED"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GMED", "name": "Globus Medical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/972d701d-351a-4b7f-9a57-4b2bb8d46398/"}]}}, {"id": "source:236f34736a111bb242258345d7e1c88edda917f48b269c364f2bb5538f36f2f3", "url": "https://finance.yahoo.com/healthcare/articles/abbott-big-ten-bring-back-131400198.html", "external_url": "https://finance.yahoo.com/healthcare/articles/abbott-big-ten-bring-back-131400198.html", "title": "Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis", "content_text": "\"We Give Blood\" brings together all 18 Big Ten\u00ae schools in a competition to drive the most blood donations and win $1 million from global healthcare company Abbott For only the second time in its history, the American Red Cross has declared a national blood crisis after donations dropped to a four-year summer low, threatening the availability of lifesaving blood for patients across the country Abbott and the Big Ten urge people to donate blood now and will count those early donations toward the competition, which officially kicks off Aug. 26 Anyone can donate blood anywhere in the U.S. between", "date_published": "2026-08-12T13:14:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ABT"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/087c1c3d-b101-4e93-9e9f-1d2d4bc0dadf/"}]}}, {"id": "source:578a0f2db601796dd5dbafacfdc29748269b258cca81fd8d2fed95ac1f7dea2e", "url": "https://finance.yahoo.com/healthcare/articles/does-medtronic-mdt-still-trade-023547555.html", "external_url": "https://finance.yahoo.com/healthcare/articles/does-medtronic-mdt-still-trade-023547555.html", "title": "Does Medtronic (MDT) Still Trade At A Discount After Its CE Mark Win?", "content_text": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Medtronic stock has delivered a 20.8% gain over the past three years, yet current checks suggest it now sits close to its estimated intrinsic value rather than at a clear discount. At the same time, earnings-based multiples still screen the shares as undervalued, which sets up a debate over how much upside is left from here. A 20.8% return over three years points to steady value creation for Medtronic shareholders, not a rapid rerating. Progress in highe", "date_published": "2026-08-12T02:35:47+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDTN"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDTN", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/29c47170-35d2-4239-972f-dcfecaf5bd5e/"}]}}, {"id": "source:640f91104b792f847e01800e8eb1613daed98a78b72905c44aa08b953c433f86", "url": "https://finance.yahoo.com/healthcare/articles/stryker-syk-comeback-quarter-looks-212323255.html", "external_url": "https://finance.yahoo.com/healthcare/articles/stryker-syk-comeback-quarter-looks-212323255.html", "title": "Stryker\u2019s (SYK) Comeback Quarter Looks Great, But At What Cost?", "content_text": "Stryker (NYSE:SYK) turned in one of its stronger quarters in recent memory on July 30, with sales climbing 9.4% to $6.6 billion and reported EPS jumping 44.1% to $3.30. The numbers arrive as the company works its way back from a cyber incident that had rattled its business, and CEO Kevin Lobo pointed to that recovery as proof of the company's resilience. But a closer look at how those earnings were adjusted tells a more complicated story about what is really driving the bottom line.Stryker's (SYK) Comeback Quarter Looks Great, But At What Cost? Bull Case: Growth That Touched Every Corner Of Th", "date_published": "2026-08-11T21:23:23+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "SYK"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SYK", "name": "Stryker Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/8cb91a3d-97c1-4ed6-a1cb-ce513180216f/"}]}}, {"id": "source:87f3f3c3d7a52b0e838831f823951d5707a7816c1b703a90b5d58c54f9f329f6", "url": "https://finance.yahoo.com/markets/stocks/articles/medtronic-mdt-wins-analyst-upgrades-191512624.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/medtronic-mdt-wins-analyst-upgrades-191512624.html", "title": "Medtronic (MDT) Wins Analyst Upgrades, Is It Fully Priced?", "content_text": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Medtronic (MDT) has moved back into focus after multiple analyst upgrades tied to what they describe as the company's strongest annual revenue growth in a decade, supported by its cardiac portfolio and new product launches. See our latest analysis for Medtronic. Over the past quarter Medtronic has picked up momentum, with a 90 day share price return of 16.39% and a 30 day gain of 6.61%, while the 1 year total shareholder return is close to flat and the 5", "date_published": "2026-08-11T19:15:12+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDTN"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDTN", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/29c47170-35d2-4239-972f-dcfecaf5bd5e/"}]}}, {"id": "source:a93731d0c9c40eb23dcb21e7d72b4b1b03117182e350815ead3bff07ebac932a", "url": "https://finance.yahoo.com/video/arrow-exploration-confirms-four-zones-174110053.html", "external_url": "https://finance.yahoo.com/video/arrow-exploration-confirms-four-zones-174110053.html", "title": "Arrow Exploration confirms four zones at Icaco 3, opens up ~10 new drilling locations", "content_text": "Arrow Exploration Corp (TSX-V:AXL, AIM:AXL, OTC:CSTPF) CEO Marshall Abbott tells Proactive's Stephen Gunnion that the Icaco 3 well has confirmed up to four hydrocarbon-bearing zones in the Icaco extension of the Tapir Block in Colombia, opening almost 10 additional development locations across the Ubaque, Guadalupe and Carbonera C7 intervals. The IC-HZ4 and IC-HZ5 horizontal wells encountered a record Ubaque thickness of over 100 feet, containing 13.7 API crude, with Abbott saying the Ubaque trend extends across the northern part of the Tapir Block, supporting further development drilling. With five new water disposal cellars complete, Arrow is preparing to skid its rig and drill continuously until at least June next year. Abbott said production currently sits above 5,000 boe/d, with the programme expected to push output \"well north\" of that level. The company remains cash-flow positive above its capex spend, and Abbott said the current oil price environment supports a more aggressive drilling stance. On the Tapir Block licence extension, Abbott said he recently met Colombia's national regulator and Ecopetrol in Bogota, pointing to Arrow's track record of five discoveries, 40 development wells and $127 million invested as evidence it's the type of explorer authorities want. He described dialogue as \"very positive,\" with a decision expected before year-end. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy #ArrowExploration #AXL #oilexploration #crudeoil #Colombia #TapirBlock #Icaco #Ecopetrol #energystocks #resourceinvesting View Comments", "date_published": "2026-08-11T17:41:10+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ABT"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/087c1c3d-b101-4e93-9e9f-1d2d4bc0dadf/"}]}}, {"id": "source:f9934b85d4d07a07af4b86760fb38b6cf174ed6a2960e42925eb1492a00e8735", "url": "https://finance.yahoo.com/healthcare/articles/cah-q4-earnings-beat-pharma-162100894.html", "external_url": "https://finance.yahoo.com/healthcare/articles/cah-q4-earnings-beat-pharma-162100894.html", "title": "CAH Q4 Earnings Beat on Pharma Strength, Revenues Miss, Stock Up", "content_text": "Cardinal Health, Inc. CAH reported fourth-quarter fiscal 2026 adjusted earnings per share (EPS) of $2.91, beating the Zacks Consensus Estimate by 20.3%. The bottom line improved 40% year over year, aided by higher operating earnings, IEEPA tariff refunds, a lower tax rate and a reduced share count. GAAP EPS in the quarter was $1.70 compared with $1.00 in the year-ago period. Full-year fiscal 2026 adjusted EPS was $11.26, up 37% compared to the figure at the end of the fiscal 2025 period. The company reported GAAP EPS of $7.23 in fiscal 2026, compared with $6.45 in the year-ago period. Q4 Reven", "date_published": "2026-08-11T16:21:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GMED"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GMED", "name": "Globus Medical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/972d701d-351a-4b7f-9a57-4b2bb8d46398/"}]}}, {"id": "source:bcb4764581f4a076fb7e9abf31a2d7f99a1c6e3455c12630d4326d1df1680524", "url": "https://finance.yahoo.com/markets/stocks/articles/globus-medical-gmed-upgraded-strong-160003167.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/globus-medical-gmed-upgraded-strong-160003167.html", "title": "Globus Medical (GMED) Upgraded to Strong Buy: Here's Why", "content_text": "Globus Medical (GMED) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. Since a changing earnings picture is a powerful factor influencing near-term stock price movements", "date_published": "2026-08-11T16:00:03+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "GMED"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GMED", "name": "Globus Medical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/972d701d-351a-4b7f-9a57-4b2bb8d46398/"}]}}, {"id": "source:b91885cda0f85fb0f0df971936b07f492f85095435d3e507b97958dacee42f47", "url": "https://finance.yahoo.com/markets/stocks/articles/gmed-vs-itgr-stock-better-154003565.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/gmed-vs-itgr-stock-better-154003565.html", "title": "GMED vs. ITGR: Which Stock Is the Better Value Option?", "content_text": "Investors interested in Medical - Instruments stocks are likely familiar with Globus Medical (GMED) and Integer (ITGR). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits. Currently, Globus Medical ", "date_published": "2026-08-11T15:40:03+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GMED"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GMED", "name": "Globus Medical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/972d701d-351a-4b7f-9a57-4b2bb8d46398/"}]}}, {"id": "source:2167fffa799a4cde18062ad463ab29372646ba681a5a4a8c75f87e744765b744", "url": "https://finance.yahoo.com/markets/stocks/articles/ge-healthcare-technologies-gehc-just-133002443.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/ge-healthcare-technologies-gehc-just-133002443.html", "title": "GE HealthCare Technologies (GEHC) Just Overtook the 200-Day Moving Average", "content_text": "GE HealthCare Technologies (GEHC) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, GEHC broke through the 200-day moving average, which suggests a long-term bullish trend. The 200-day simple moving average helps traders and analysts determine overall long-term market trends for stocks, commodities, indexes, and other financial instruments. The indicator moves higher or lower along with longer-term price moves, serving as a support or resistance level. Shares of GEHC have been moving higher over the past four weeks, up 11.7%. Pl", "date_published": "2026-08-11T13:30:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GEHC"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GEHC", "name": "GE HealthCare Technologies Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b7898e81-253f-4173-8645-02e09a305a8f/"}]}}, {"id": "source:9b0747406a31f261a432fba0c0e5eb1aba2c71244b46ea5c19d6bb0ddefce0e0", "url": "https://finance.yahoo.com/healthcare/articles/abbott-google-launch-first-kind-130000853.html", "external_url": "https://finance.yahoo.com/healthcare/articles/abbott-google-launch-first-kind-130000853.html", "title": "Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI", "content_text": "Multi-year collaboration combines ongoing glucose insights from Abbott's Lingo biowearable with Google Health's technology to create a more comprehensive view of personal health Partnership includes a large-scale research study to better inform artificial intelligence (AI) coaching available in the Google Health app and future Lingo product features Lingo, Abbott's over-the-counter continuous glucose monitor (CGM), helps people understand the impact of nutrition, activity, sleep and stress on their glucose so they can make meaningful lifestyle changes ABBOTT PARK, Ill., Aug. 11, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a first-of-its-kind partnership with Google Health to redefine how people understand and manage their health. By combining glucose insights from Abbott's Lingo biowearable with Google's expertise in artificial intelligence (AI) and consumer technology, the multi-year collaboration makes personalized metabolic insights more actionable, helping people take a more proactive approach to their health. The collaboration is designed to bring metabolic health insights into people's daily routines through a seamless, AI-powered experience. Through the Google Health app, Lingo users will be able to view glucose trends alongside other health and wellness metrics in a unified experience, helping them better understand how daily behaviors influence their overall well-being. Google's Health Coach will use these insights to deliver personalized, contextual recommendations designed to help users build sustainable habits related to nutrition, activity, sleep and recovery. The partnership will focus on three areas: Connecting glucose data to a more complete picture of health: Integrating ongoing glucose insights from the Lingo continuous glucose monitor (CGM) into Google Health to help users understand their body's response to daily habits and make better lifestyle and nutrition choices in the moment. Delivering AI-powered, personalized health guidance: Combining glucose insights with Google Health Coach to provide tailored recommendations that help people build healthier habits. Establishing new science about metabolic health: Conducting one of the largest real-world metabolic health studies to date, integrating continuous glucose, wearable, laboratory, and survey data to uncover connections between activity, sleep, wellbeing, and metabolic health, informing more personalized guidance that supports healthier day-to-day decisions. Rates of metabolic health challenges continue to rise globally. Prediabetes, one of the fastest-growing health crises in the U.S., impacts over 115 million American adults with more than 2 in 5 adults affected and approximately 8 in 10 are completely unaware they have it.[1] Additionally, poor metabolic health can lead to other chronic conditions such as Type 2 diabetes, cardiovascular disease and certain cancers.[2] The partnership between Abbott and Google Health aims to help people better understand the connection between their daily habits and overall well-being, empowering earlier and more informed action to help slow the development and progression of conditions related to poor metabolic health. Story Continues \"The biggest challenge in healthcare isn't treating disease\u2014it's helping people stay healthier longer,\" said Olivier Ropars, divisional vice president of Abbott's Lingo business. \"Abbott's leadership in biowearables and Google's expertise in AI and consumer technology create a powerful opportunity to make personalized insights available at unprecedented scale. Additionally, we are advancing metabolic health research through one of the largest real-world studies of its kind, generating new insights into the relationship between glucose and everyday behaviors. That research will help shape future AI-powered guidance and metabolic health innovation. Together, we can help people better understand their bodies and take action before health challenges become health conditions.\" Lin", "date_published": "2026-08-11T13:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ABT"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/087c1c3d-b101-4e93-9e9f-1d2d4bc0dadf/"}]}}, {"id": "source:1c8e1137cbdd39b6aea8b289794d24a367c007eba5a577b44e7c22e467624381", "url": "https://finance.yahoo.com/healthcare/articles/abbott-vs-medtronic-consistent-growth-224625108.html", "external_url": "https://finance.yahoo.com/healthcare/articles/abbott-vs-medtronic-consistent-growth-224625108.html", "title": "Abbott vs. Medtronic: Is Consistent Growth Better Than a Turnaround Story?", "content_text": "Abbott Laboratories (NYSE:ABT) and Medtronic (NYSE:MDT) are both prominent names in the Medtech space. Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes. Medtronic (NYSE:MDT), meanwhile, continued to build on its turnaround, reporting its strongest annual revenue growth in a decade as several high-growth platforms gained momentum. So, which is the more compelling long-term investment opportunity: Abbott's (NYSE:ABT) consistent execution or Medtronic's (NYSE:MDT) improving growth trajectory?Spectral AI (MDAI) Secures $17.7 Million to Launch Burn Wound AI System A patient viewing their medical diagnosis on a digital healthcare ecosystem. Bull Case Abbott's (NYSE:ABT) second-quarter results reinforced one of the company's biggest competitive advantages: its ability to generate growth from multiple businesses simultaneously. While investors often focus on its medical device portfolio, diagnostics emerged as one of the strongest contributors during the quarter. Sales in its diagnostics segment rose 42% to $3.09 billion in fiscal Q2, surpassing the estimate \u200bof $3.02 billion, emerging as one of the company's strongest performers during the quarter. Its cancer \u2060diagnostics business, which was recently integrated through the Exact Sciences buyout, is benefiting from an expanding base that comprises both new and repeat users of the colorectal cancer screening test, Cologuard. Furthermore, Abbott Laboratories (NYSE:ABT) reaffirmed its full-year 2026 comparable sales growth guidance of 6.5% to 7.5%, suggesting confidence in its operations. The company also raised its full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to the previous range of $5.38 to $5.58. While Abbott's (NYSE:ABT) investment case centers on diversification and consistent execution, Medtronic's (NYSE:MDT) appeal increasingly lies in whether its long-awaited turnaround is finally taking hold. One of the most prominent factors supporting Medtronic's (NYSE:MDT) turnaround story is the company's reporting of its highest annual revenue growth in 10 years in its fiscal Q4 and full-year 2026 results. Q4 revenue reached $9.8 billion, up 9.9% as reported and 6.6% organic, and FY 26 revenue was $36.4 billion, adjusted revenue of $36.3 billion, up 8.4% as reported and 5.8% organic. Those results suggest Medtronic's (NYSE:MDT) recovery is becoming increasingly broad-based rather than relying on a single product cycle, an important distinction for investors evaluating whether the turnaround is sustainable, especially in its highest growth opportunities such as Affera, Symplicity, Hugo, Altaviva, and Stealth AXiS. Story Continues Beyond the headline numbers, Medtronic's (NYSE:MDT) newer growth platforms are continually gaining traction. Symplicity Spyral for hypertension is now annualizing at approximately $100 million in revenue, while products such as Hugo and Affera continue expanding the company's exposure to faster-growing MedTech markets. BTIG also recently argued that improving sentiment across the broader MedTech sector could provide an additional tailwind if utilization trends remain healthy. Bear Case Abbott's (NYSE:ABT) second-quarter results were undoubtedly strong, but the company's full-year outlook still relies on a stronger second half. While management raised its adjusted EPS guidance, it reaffirmed rather than increased its comparable sales growth outlook of 6.5% to 7.5%, suggesting that it remains measured on the pace of revenue growth. The company is also counting on several pipeline products to contribute more meaningfully in the second half of 2026 and into fiscal 2027. If those launches ramp more slowly than expected, the acceleration implied by management's outlook could prove more difficult to achieve. Similarly", "date_published": "2026-08-10T22:46:25+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ABT"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/087c1c3d-b101-4e93-9e9f-1d2d4bc0dadf/"}]}}, {"id": "source:d3ab2b7502c0abaac5cde1db78f3d61c3eea5a4004021eb3d7b5a05c0c8bffc5", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-vs-abbott-laboratories-204959195.html", "external_url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-vs-abbott-laboratories-204959195.html", "title": "Johnson & Johnson vs Abbott Laboratories: Which Healthcare Giant Offers the More Compelling Growth Story After Earnings?", "content_text": "Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 \u2060billion, above analysts' average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised its guidance and stated that it is on track to meet its 2026 goal of over $100 billion in annual revenue for the first time in its 140-year history. Abbott Laboratories (NYSE:ABT) also beat its quarterly estimates in its fiscal Q2 2026 results while also raising its annual profit forecast, with strong demand for its cancer diagnostics business and medical devices easing procedure-volume concerns. Sales for the quarter rose 13% on a reported basis and 4.8% on a comparable basis. So which healthcare giant offers the more compelling investment case for investors? Let's dive into it.Citi Believes Abbott (ABT) Shares are Undervalued Relative to Business Segments An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. Both healthcare giants beat quarterly estimates and raised their outlooks, suggesting continued resilience across their businesses. The key question for investors is whether Johnson & Johnson's (NYSE:JNJ) pharmaceutical growth story or Abbott Laboratories' (NYSE:ABT) expanding diagnostics and medical devices businesses offer the more compelling investment case going forward. Bull Case Johnson & Johnson's (NYSE:JNJ) pharmaceutical unit was an optimistic factor, as it helped increase total sales, generating $16.38 billion in quarterly sales and exceeding analysts' estimate of $16.1 billion. The healthcare giant now expects its annual sales to be around $101.1 billion at the midpoint, \u200bcompared with $100.8 billion \u2060previously. In another optimistic feat, it raised its adjusted earnings per share forecast to $11.68 at the midpoint, from a previous $11.55 per share. Revenue from Johnson & Johnson's (NYSE:JNJ) Stelara, which treats psoriasis, Crohn's disease, and \u200bother autoimmune conditions, dropped over 55% in the quarter to $740 million due to patent loss. However, the company's cancer and newer immunology drugs can be seen countering this loss, as sales of Tremfya, its psoriasis and inflammatory bowel disease drug, rose 72.5% to $2 billion, considerably exceeding the estimate of $1.74 billion. The most encouraging sign for investors thus may be Johnson & Johnson's (NYSE:JNJ) ability to absorb a significant patent-related decline in Stelara sales while still raising its full-year outlook. Strong performance from newer drugs such as Tremfya suggests the company's pipeline is successfully offsetting losses from older products. Story Continues On the other hand, Abbott Laboratories (NYSE:ABT) reported GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31, which excludes specified items, and reaffirmed its full-year 2026 comparable sales growth guidance of 6.5% to 7.5%, suggesting confidence in its operations. The company also raised its full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to the previous range of $5.38 to $5.58. Abbott Laboratories (NYSE:ABT) diagnostics segment rose 42% to $3.09 billion in fiscal Q2, surpassing the estimate \u200bof $3.02 billion, emerging as one of the company's strongest performers during the quarter. This was driven by strong adoption in electrophysiology, diabetes care (such as CGM systems), and expanding cancer screening diagnostics. William Blair stated that the company's cancer diagnostics results should improve sentiment around the Exact Sciences \u200bacquisition, with growth in medical devices helping offset concerns surrounding hospital procedure volumes. Bear Case Johnson & Johnson's (NYSE:JNJ) MedTech segment was comparatively less impressive during the quarter, with sales slightly missing expectations. Management attributed some of the weakness to temporary headwinds, including inventory-related pressures in China t", "date_published": "2026-08-10T20:49:59+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ABT"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/087c1c3d-b101-4e93-9e9f-1d2d4bc0dadf/"}]}}, {"id": "source:7703f3386bdf9c30a1da14a667b6a0c799897c5eec25c59526fc361155dd0b1c", "url": "https://finance.yahoo.com/markets/stocks/articles/boston-scientific-ceo-mahoney-buys-174601248.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/boston-scientific-ceo-mahoney-buys-174601248.html", "title": "Boston Scientific CEO Mahoney Buys More Than 200k Shares for $10 Million. What Does This Mean for Investors in 2026?", "content_text": "Michael F. Mahoney, Chairman, President & CEO of Boston Scientific Corporation (NYSE:BSX), purchased 186,240 shares of common stock at $48.34 per share on August 3, 2026. SEC Form 4 filing. Transaction summary Metric Value Transaction value $10.1 million Shares purchased 208,359 Post-transaction shares (total) 1,612,143 Post-transaction shares (directly held) 1,590,024 Post-transaction shares (indirectly held) 22,119 Post-transaction value $78.08 million Transaction value based on SEC Form 4 weighted average purchase price ($48.34); post-transaction value based on August 03, 2026 market close ", "date_published": "2026-08-10T17:46:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BSX"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BSX", "name": "Boston Scientific Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/cb16eae5-5514-43b3-85b0-63b078829e89/"}]}}, {"id": "source:390765aa7addb2236810f0ab23ac9e6d6081e06b54be92e59ed0289d5d56666d", "url": "https://finance.yahoo.com/markets/stocks/articles/buy-hold-sell-abt-stock-144300730.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/buy-hold-sell-abt-stock-144300730.html", "title": "Should You Buy, Hold or Sell ABT Stock Amid Medical Devices Boom?", "content_text": "Abbott Laboratories' ABT Medical Devices remains its largest segment and continues to benefit from a strong pipeline of new product launches and growing adoption across cardiovascular care and diabetes management. The segment is well positioned to capitalize on the expanding global medical devices market. According to Fortune Business Insights, the global medical devices market was valued at $572.31 billion in 2025 and is projected to increase from $604.99 billion in 2026 to $1.03 trillion by 2034, reflecting a CAGR of 6.9% over the forecasted period. Given this favorable industry backdrop, Abbott's Medical Devices business maintained solid momentum in the second quarter of 2026, with sales increasing 8.4% on a comparable basis. Electrophysiology sales advanced 13.4%, while Rhythm Management, Heart Failure and Diabetes Care each delivered high-single-digit comparable growth. Notably, continuous glucose monitoring sales exceeded $2 billion, supported by the scale of Abbott's FreeStyle Libre franchise and its expanding adoption. Despite these encouraging growth trends, the broader Medical Devices sector continues to face macroeconomic headwinds, including policy uncertainty, persistent cost inflation and tariff-related pressures. These factors could weigh on operating costs and investor sentiment across the industry. Abbott shares have lost approximately 17.9% over the past year compared with a 23.9% decline for the broader Medical Products industry. During the same period, shares of key peers Boston Scientific BSX and GE HealthCare Technologies GEHC have declined 52% and 1.7%, respectively.Zacks Investment Research Image Source: Zacks Investment Research Major Tailwinds for ABT Stock EPD Momentum Across Emerging Markets: Abbott's Established Pharmaceuticals Division (\"EPD\") remains a steady contributor, supported by branded generics positions in faster-growing geographies. In the second quarter of 2026, EPD sales increased 8.4% on a reported basis and 8.7% on a comparable basis. Key emerging markets grew 10.7% on a comparable basis, led by double-digit growth in several countries across Latin America and Asia Pacific. The company is also expanding its biosimilar pipeline, which should deepen the portfolio in key markets. It expects EPD to sustain high-single-digit sales growth over time, supported by broad geographic demand, brand equity and disciplined commercial execution. Innovation-Led Reset in Nutrition: Abbott is working through a transition in Nutrition that is intended to restore a healthier balance between price and volume over time. In the second quarter of 2026, Nutrition sales increased $127 million sequentially as both Pediatric and Adult Nutrition improved. International Pediatric Nutrition returned to growth, rising 6.4% on a comparable basis, while recent Special Supplemental Nutrition Program for Women, Infants, and Children (\"WIC\") contract wins lifted Abbott to the leading position in both WIC and non-WIC channels. Story Continues In Adult Nutrition, U.S. retail consumption of Ensure increased at a double-digit rate from 2025-end levels, and international sales approached prior-year levels. New Ensure products with higher protein, lower sugar and refreshed packaging are also contributing. The company expects pricing actions, new products and commercial execution to support continued improvement in the second half of 2026. Estimates for ABT Heading North The Zacks Consensus Estimate for Abbott's 2026 sales and EPS implies a year-over-year improvement of 13.5% and 9.2%, respectively. The bottom-line estimates have shown upward movement in the past 30 days.Zacks Investment Research Image Source: Zacks Investment Research ABT's Downsides China Policy Risk Persists: China remains a source of uncertainty, particularly within Core Laboratory Diagnostics where volume-based procurement (VBP) has affected pricing and sales. Abbott mentioned that the China business had declined around 30% for at least five quarters befo", "date_published": "2026-08-10T14:43:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ABT"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/087c1c3d-b101-4e93-9e9f-1d2d4bc0dadf/"}]}}, {"id": "source:c0ac9562cdc93b8911e716f74d7679e0dafab3d4c3575d0891a9a57cfbedf88e", "url": "https://finance.yahoo.com/healthcare/articles/podds-q2-earnings-top-estimates-132200272.html", "external_url": "https://finance.yahoo.com/healthcare/articles/podds-q2-earnings-top-estimates-132200272.html", "title": "PODD's Q2 Earnings Top Estimates, FY'26 Sales View Cut, Stock Down", "content_text": "Insulet Corporation PODD reported second-quarter 2026 adjusted earnings per share (EPS) of $1.66, up 41.5% year over year. The bottom line beat the Zacks Consensus Estimate by 15.28%. GAAP EPS came in at $1.37 compared with the year-ago quarter's figure of 32 cents. Revenues of $801.7 million rose 23.5% and surpassed the consensus mark by 1.89%, reflecting broad-based Omnipod demand and favorable price mix. Following the announcement on Aug. 5, PODD shares have dropped nearly 20% to end the session at $133.26. PODD's Omnipod Sales Stay Strong Total Omnipod revenues advanced 24.6% to $795.9 mil", "date_published": "2026-08-10T13:22:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PODD"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PODD", "name": "Insulet Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/ddc4e846-4b3d-49f0-9696-0f35675b981e/"}]}}, {"id": "source:455f96e15db4bb8b0af01b95c9642b11502fa4455a603549f01df4629a717c6c", "url": "https://finance.yahoo.com/healthcare/articles/medtronic-mdt-becoming-turnaround-story-234359487.html", "external_url": "https://finance.yahoo.com/healthcare/articles/medtronic-mdt-becoming-turnaround-story-234359487.html", "title": "Is Medtronic (MDT) Becoming a Turnaround Story?", "content_text": "UBS upgraded Medtronic (NYSE:MDT) to a Buy from Neutral today, telling investors in a research note that a \"turnaround\" is underway at the company. The upgrade raises an important question for investors: Is Medtronic finally returning to sustainable growth after years of underperformance, or is it too early to call the turnaround complete?Truist Maintains Hold on Medtronic (MDT), Seeks Stronger EPS Growth Bull case One of the most prominent factors supporting Medtronic's (NYSE:MDT) turnaround story is the company's reporting of its highest annual revenue growth in 10 years in its fiscal Q4 and", "date_published": "2026-08-09T23:43:59+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDTN"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDTN", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/29c47170-35d2-4239-972f-dcfecaf5bd5e/"}]}}, {"id": "source:d57b5b18af87a6c4c97d2c4c28d98cf6f03ef2e7928b939a0fe59ecb5ec288c0", "url": "https://seekingalpha.com/news/4629554-notable-healthcare-headlines-for-the-week-eli-lilly-novo-nordisk-and-pfizer-in-focus?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4629554-notable-healthcare-headlines-for-the-week-eli-lilly-novo-nordisk-and-pfizer-in-focus?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Pfizer in focus", "content_text": "Wall Street\u2019s major market averages ended higher on Friday after July's nonfarm payrolls surprised to the downside, showing an unexpected contraction in employment. The blue-chip Dow edged up 0.3%, the benchmark S&P 500 gained 0.62%, and the tech-focused Nasdaq Composite jumped 1.3%. The S&P 500 Health Care Index Sector (XLV [https://seekingalpha.com/symbol/XLV]) gained 1.92% during the week. The top S&P 500 healthcare gainers and losers for the last week are as follows: TOP GAINERS: Charles River Laboratories International (CRL [https://seekingalpha.com/symbol/CRL]) +15.04% Veeva Systems (VEE", "date_published": "2026-08-09T13:05:04+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "PODD"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PODD", "name": "Insulet Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/ddc4e846-4b3d-49f0-9696-0f35675b981e/"}]}}, {"id": "source:1fddf4e93a1a54052bd0c57eff4ffbbad6d8224302d085e45c2368f7f2416892", "url": "https://www.globenewswire.com/news-release/2026/08/09/3341477/673/en/transmedics-group-inc-investor-news-rosen-law-firm-announces-investigation-of-breaches-of-fiduciary-duties-by-the-directors-and-officers-of-transmedics-group-inc-tmdx.html", "external_url": "https://www.globenewswire.com/news-release/2026/08/09/3341477/673/en/transmedics-group-inc-investor-news-rosen-law-firm-announces-investigation-of-breaches-of-fiduciary-duties-by-the-directors-and-officers-of-transmedics-group-inc-tmdx.html", "title": "TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. \u2013 TMDX", "content_text": "NEW YORK, Aug. 08, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). If you currently own shares of TransMedics Group stock, please visit the firm\u2019s website at https://rosenlegal.com/cases/transmedics-group-inc/join for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at case@rosenlegal.com. Why Rosen Law: We encourage investors to select qualified counsel with a track r", "date_published": "2026-08-09T03:49:00+00:00", "authors": [{"name": "globenewswire.com"}], "tags": ["Regulatory and legal", "TMDX"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TMDX", "name": "TransMedics Group, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/0dd8653e-b31e-4256-a010-a3616a76aef1/"}]}}, {"id": "source:cfa2e9eeef0f04003ff3ff3d17190b682d47e0feabacf8398b58a2ff1baa3870", "url": "https://www.nasdaq.com/articles/medtronic-vs-intuitive-surgical-which-medtech-stock-better-buy-right-now", "external_url": "https://www.nasdaq.com/articles/medtronic-vs-intuitive-surgical-which-medtech-stock-better-buy-right-now", "title": "Medtronic vs. Intuitive Surgical: Which MedTech Stock Is the Better Buy Right Now?", "content_text": "Key Points Medtronic has launched new devices that will help further improve its financial results. Intuitive Surgical's latest da Vinci system could expand its addressable market. Each stock will appeal to investors with different priorities. 10 stocks we like better than Medtronic \u203a Medtronic(NYSE: MDT) and Intuitive Surgical(NASDAQ: ISRG), two medical device leaders, haven't performed well this year. While weakness in the broader healthcare sector hasn't helped, they have both encountered company-specific issues that have contributed to their lagging the market. The good news is that there ", "date_published": "2026-08-08T21:20:00+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "MDTN"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDTN", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/29c47170-35d2-4239-972f-dcfecaf5bd5e/"}]}}, {"id": "source:053419f368676f2469ea023f4e0a3e1b2e945ed3c1994c5c34801aa4bc954f69", "url": "https://finance.yahoo.com/markets/stocks/articles/abbott-laboratories-abt-could-10-161147968.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/abbott-laboratories-abt-could-10-161147968.html", "title": "Abbott Laboratories (ABT) Could Be 10% Undervalued On Its $1.35b Buyback Update", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Abbott Laboratories buyback update Abbott Laboratories (ABT) has completed a share repurchase tranche that saw the company buy back 14,015,097 shares for about US$1.35b, including 11,599,094 shares between April and June 2026. See our latest analysis for Abbott Laboratories. Abbott Laboratories shares trade at US$107.81 and have gained 27.86% over the past 90 days, while the year-to-date share price return is down 13.19% and the 1-year total shareholder return is down 17.86%. This points to improving short-term momentum after a weaker period. Recent drivers include the completed US$1.35b buyback program and the April acquisition of Exact Sciences, alongside lower 2026 guidance linked to earnings dilution from that deal. If you are looking beyond Abbott Laboratories for other healthcare ideas, this could be a good moment to scan for companies at the crossroads of medicine and AI using our 43 healthcare AI stocks Abbott Laboratories has rebounded sharply in the last quarter after a weaker year and a US$23b acquisition that diluted guidance. Is this just a catch up move, or does the current valuation leave meaningful upside ahead? Most Popular Narrative: 9.5% Undervalued The most followed narrative currently places Abbott Laboratories' fair value at $119.13, which sits above the last close at $107.81 and frames the recent rebound in a valuation context. The expansion of healthcare access and rising middle class in key emerging markets (such as India, China, Latin America, and the Middle East) is fueling robust growth in branded generics and biosimilars, highlighted by Abbott's record sales in these regions and imminent biosimilar launches; this trend is described as a potential driver of ongoing double-digit top-line growth and greater geographic revenue diversification. Read the complete narrative. Want to understand why this narrative still justifies a premium multiple on future earnings? The key is how revenue growth, margin expansion and a richer product mix interact over the next few years. Result: Fair Value of $119.13 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Abbott Laboratories still faces key risks, including pricing pressure in diagnostics and glucose monitoring, as well as potential earnings drag from tariffs and foreign exchange moves. Find out about the key risks to this Abbott Laboratories narrative. Story Continues Next Steps The mix of risks and rewards around Abbott Laboratories is clear, so it makes sense to review the data yourself and decide quickly where you stand. To see both sides in one place, start with these 3 key rewards and 2 important warning signs Looking for more Abbott Laboratories investment ideas? If you follow Abbott Laboratories, do not stop here. Use this moment to broaden your watchlist and compare other opportunities that might fit your goals even better. Target strong value potential by scanning companies that combine quality fundamentals with attractive pricing using our 51 high quality undervalued stocks. Boost your income focus by reviewing businesses with higher yields and resilient payout histories via our 8 dividend fortresses. Protect your downside by assessing companies with stronger balance sheets and cleaner financial profiles through our solid balance sheet and fundamentals stocks screener (49 results). This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest pric", "date_published": "2026-08-08T16:11:47+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ABT"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABT", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/087c1c3d-b101-4e93-9e9f-1d2d4bc0dadf/"}]}}, {"id": "source:1976f33177867bb81de244cbdee9e6f54a517f8c907081aed7eea164f1038413", "url": "https://finance.yahoo.com/healthcare/articles/globus-medical-q2-earnings-call-100346741.html", "external_url": "https://finance.yahoo.com/healthcare/articles/globus-medical-q2-earnings-call-100346741.html", "title": "Globus Medical Q2 Earnings Call Highlights", "content_text": "Key Points Interested in Globus Medical, Inc.? Here are five stocks we like better. Q2 revenue rose 6% to $789.6 million, while record non-GAAP EPS increased 56% to $1.34 and adjusted EBITDA margin expanded to 35.4%. Spine and trauma growth offset declines in enabling technologies and Nevro. Musculoskeletal revenue grew 8%, led by 7% U.S. spine growth, 12% constant-currency international spine growth and a 31% increase in trauma revenue. Robotic-equipment placements also increased despite lower reported enabling-technologies revenue as the company shifts toward leasing and rental models. Globu", "date_published": "2026-08-08T10:03:46+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GMED"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GMED", "name": "Globus Medical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/972d701d-351a-4b7f-9a57-4b2bb8d46398/"}]}}, {"id": "source:8a4a791cca70b4beebb809c5f2a1ed4b675fe78145cbd17af5a9f36e22a31096", "url": "https://finance.yahoo.com/healthcare/articles/medtronic-mdt-wins-expanded-ce-020910766.html", "external_url": "https://finance.yahoo.com/healthcare/articles/medtronic-mdt-wins-expanded-ce-020910766.html", "title": "Medtronic (MDT) Wins Expanded CE Mark For Affera System In Ventricular Arrhythmias", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Medtronic (NYSE:MDT) receives expanded CE Mark indication for its Affera Mapping and Ablation System and Sphere-9 Catheter for ventricular arrhythmia treatment. The Sphere-9 catheter also holds a Breakthrough Device Designation from the U.S. FDA, which highlights its potential clinical impact. This broader regulatory progress could influence Medtronic's position in cardiac arrhythmia care across international markets. As cardiac care technology evolves and Medtronic advances ", "date_published": "2026-08-08T02:09:10+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MDTN"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDTN", "name": "Medtronic plc", "sentiment_url": "https://sharemaestro.com/sentiment/29c47170-35d2-4239-972f-dcfecaf5bd5e/"}]}}, {"id": "source:0430c59c3e06fa7c605501d25add16896d0864a67a6c21fcdb18e4d186dc3014", "url": "https://finance.yahoo.com/healthcare/articles/boston-scientific-bsx-recalls-mean-190939502.html", "external_url": "https://finance.yahoo.com/healthcare/articles/boston-scientific-bsx-recalls-mean-190939502.html", "title": "What Do Boston Scientific (BSX) Recalls Mean For Device Safety And Clinical Use?", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Boston Scientific (NYSE: BSX) has initiated multiple product recalls covering cardiac ablation generators and vascular access sheaths due to labeling discrepancies and air embolism risks. The recalls affect a broad mix of devices used in cardiac and vascular procedures across several international markets. Regulators and hospitals are assessing the implications for device safety protocols, clinical workflows, and future use of the impacted products. Produc", "date_published": "2026-08-07T19:09:39+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "BSX"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BSX", "name": "Boston Scientific Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/cb16eae5-5514-43b3-85b0-63b078829e89/"}]}}, {"id": "source:68d0b7541a2d95f095b70a36b8744deea4f5c644ab01749400c1f75ec2ada435", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE5oTkQ4RUNQVHZBTzhKenFzRWp1SVk0cy0zeDB1LTVPMGR5bVJYLVVQa0JkbDQxWm9XODNfYV9OM0pvUlRGQmktSGNQRjlhUlVldFJJMjAxQmh6WGwyS2l4ZElCZHE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE5oTkQ4RUNQVHZBTzhKenFzRWp1SVk0cy0zeDB1LTVPMGR5bVJYLVVQa0JkbDQxWm9XODNfYV9OM0pvUlRGQmktSGNQRjlhUlVldFJJMjAxQmh6WGwyS2l4ZElCZHE?oc=5", "title": "Noticias de acciones de Globus Medical Inc (GMED)", "content_text": "Noticias de acciones de Globus Medical Inc (GMED)", "date_published": "2026-08-07T18:39:54+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Market update", "GMED"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GMED", "name": "Globus Medical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/972d701d-351a-4b7f-9a57-4b2bb8d46398/"}]}}, {"id": "source:b2cc62cab6c75859d0fbc20e2b0295e230cf732fff96bbcf735c283da4124183", "url": "https://news.google.com/rss/articles/CBMickFVX3lxTFB0Y1N4bzRmbFVEVFBvR09pVWRtRk5zek50TlFvNmVJSjM1dkxqcnlpX3V5R0k0UFlTQ2NReUVzSzVIX0h1VmlWdDEzT1R1TzJiUTA2bkp6c3pPcm1IV2xjZ1VMUDRoNWEyU1ctNl80OHZodw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMickFVX3lxTFB0Y1N4bzRmbFVEVFBvR09pVWRtRk5zek50TlFvNmVJSjM1dkxqcnlpX3V5R0k0UFlTQ2NReUVzSzVIX0h1VmlWdDEzT1R1TzJiUTA2bkp6c3pPcm1IV2xjZ1VMUDRoNWEyU1ctNl80OHZodw?oc=5", "title": "Globus Medical Q2 fiscal 2026: BPA no GAAP aumenta 55,8%", "content_text": "Globus Medical Q2 fiscal 2026: BPA no GAAP aumenta 55,8%", "date_published": "2026-08-07T01:41:08+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Market update", "GMED"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GMED", "name": "Globus Medical, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/972d701d-351a-4b7f-9a57-4b2bb8d46398/"}]}}, {"id": "source:0fe2c4acaa679b47b02928e3ee693f6534424e444460c884e05c9e8d8f718494", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPQTFtb1djWlY2cENqd09nMkwtckMtdjRGLUpKR3YtRDc5WXpqS3J2bENPMkdZZDFxTnNYY2RzTVg1Sy1FQzE0bHdvX2hJWmx5d01vdzB3Y0Mtb2phdE9PQXhfNUdFWlNPQmFPVU9iNVVXQ2poeHEzQm5ReVV3UTJRX3lsQUZJRjUwbHBLMWkzeWJhYU44SHdnZEN3TE9IOUpjNjlVdjVWYkJQb3lCSmc5SUxZV25wOEtsbWZvSUNGTQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPQTFtb1djWlY2cENqd09nMkwtckMtdjRGLUpKR3YtRDc5WXpqS3J2bENPMkdZZDFxTnNYY2RzTVg1Sy1FQzE0bHdvX2hJWmx5d01vdzB3Y0Mtb2phdE9PQXhfNUdFWlNPQmFPVU9iNVVXQ2poeHEzQm5ReVV3UTJRX3lsQUZJRjUwbHBLMWkzeWJhYU44SHdnZEN3TE9IOUpjNjlVdjVWYkJQb3lCSmc5SUxZV25wOEtsbWZvSUNGTQ?oc=5", "title": "Las acciones de Insulet caen tras recortar sus previsiones de ingresos", "content_text": "Las acciones de Insulet caen tras recortar sus previsiones de ingresos", "date_published": "2026-08-05T11:22:00+00:00", "authors": [{"name": "Investing.com Espa\u00f1a"}], "tags": ["Market update", "PODD"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PODD", "name": "Insulet Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/ddc4e846-4b3d-49f0-9696-0f35675b981e/"}]}}, {"id": "source:14ea12875b968577ffc1e89d2f2122d54ce0f2d00e85a776bc16967b23e9926c", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFA3enRFOEhlWHFORVNqdG5WRDk5QmgzYldySWl3N2htR3g4NWRyd3RnY2dTVFJ4VDIxUVdab1RqT1ZuMDZyZzh1MlVXYWoxWjVCWTNNbGtMb3dSZHQzWW0tY3hKbTZYUjVYbzNRZFQ2V2ZLVFU1THVOeg?oc=5", "external_url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFA3enRFOEhlWHFORVNqdG5WRDk5QmgzYldySWl3N2htR3g4NWRyd3RnY2dTVFJ4VDIxUVdab1RqT1ZuMDZyZzh1MlVXYWoxWjVCWTNNbGtMb3dSZHQzWW0tY3hKbTZYUjVYbzNRZFQ2V2ZLVFU1THVOeg?oc=5", "title": "Previsi\u00f3n de TMDX: precio objetivo 2027, TV", "content_text": "Previsi\u00f3n de TMDX: precio objetivo 2027, TV", "date_published": "2026-06-25T21:34:34+00:00", "authors": [{"name": "TradingView"}], "tags": ["Market update", "TMDX"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TMDX", "name": "TransMedics Group, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/0dd8653e-b31e-4256-a010-a3616a76aef1/"}]}}]}